Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01950741 Active, not recruiting - Clinical trials for Polypoidal Choroidal Vasculopathy

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

VAULT
Start date: September 2013
Phase: Phase 4
Study type: Interventional

Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.

NCT ID: NCT01918878 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

Start date: October 2013
Phase: Phase 4
Study type: Interventional

This is a prospective, multicenter, single arm study. The study group will be compose of NVAMD patients who had partial or complete failure responding to initial bevacizumab or ranibizumab treatment of 3-6 monthly intravitreal injections. The patients in the study groups will receive 5 intravitreal injections of aflibercept 2mg/0.05ml at specific visits. Aflibercept will be provided for total period of 24 weeks.

NCT ID: NCT01174407 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

Start date: September 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

NCT ID: NCT00370370 Active, not recruiting - Clinical trials for Neovascular Age-Related Macular Degeneration

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Start date: November 2005
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.